Find A Portfolio/Ticker
Comparison Box
MyPlanIQ
401k Investor
JOLIET ONCOLOGY HEMATOLOGY ASSOCIATES LTD. PROFIT SHARING/401K PLAN
JOLIET ONCOLOGY HEMATOLOGY ASSOCIATES LTD. PROFIT SHARING/401K PLAN Strategic Asset Allocation - Equal Weight Moderate
JOLIET ONCOLOGY HEMATOLOGY ASSOCIATES LTD. PROFIT SHARING/401K PLAN Strategic Asset Allocation - Equal Weight Moderate
live (public) 0.30% February 28
Delayed
Holdings (As of 10/31/2024)
sign up and login first and then customize a new portfolio for the latest current holdings
| Asset | Fund in this portfolio | Price change* | Original Fund Description | Percentage |
|---|---|---|---|---|
| CASH | CASH (CASH) | 0.0% | CASH | 0.00% |
| Emerging Market Equity | DFEVX (EMERGING MARKETS VALUE PORTFOLIO EMERGING MARKETS VALUE PORTFOLIO - INSTITUTIONAL CLASS) | 0.44% | DFA Emerging Markets Value Portfolio - Inst Class | 17.18% |
| Real Estate | DFREX (DFA REAL ESTATE SECURITIES PORTFOLIO DFA REAL ESTATE SECURITIES PORTFOLIO - INSTITUTIONAL CLASS) | 1.77% | DFA Real Estate Securities Portfolio - Inst Class | 17.68% |
| International Equity | RNPGX (NEW PERSPECTIVE FUND CLASS R-6) | 1.60% | American Funds New Perspective R6 | 14.48% |
| General Bond | IIBAX (VOYA INTERMEDIATE BOND FUND CLASS A) | 0.0% | Voya Intermediate Bond Fund R6 | 35.77% |
| US Equity | TBCIX (T. ROWE PRICE BLUE CHIP GROWTH FUND INC. T. ROWE PRICE BLUE CHIP GROWTH FUND-I CLASS) | 2.49% | T.Rowe Price Blue Chip Growth I | 7.08% |
| US Equity | JDEUX (JPMORGAN DISCIPLINED EQUITY FUND CLASS R6) | 1.89% | JPMorgan Emerign Markets Equity R6 | 7.81% |
* Day change on 10/31/2024.
Previous
Beta
Performance (As of 02/28/2025)
Since 12/31/2000
| Name | YTD* Return |
1Yr AR** |
3Yr AR** |
5Yr AR** |
10Yr AR** |
15Yr AR** |
|---|---|---|---|---|---|---|
| JOLIET ONCOLOGY HEMATOLOGY ASSOCIATES LTD. PROFIT SHARING/401K PLAN Strategic Asset Allocation - Equal Weight Moderate | 5.2% | 16.4% | 6.1% | 8.5% | 7.1% | 7.3% |
| VFINX (Vanguard (S&P 500) Index) | 6.0% | 14.9% | 18.3% | 16.7% | 13.3% | 14.8% |
| VBINX (Vanguard Balance (60% stocks/40% bonds) | 4.7% | 11.2% | 11.6% | 9.1% | 8.3% | 9.6% |
* YTD: Year to Date
** AR: Annualized Return
** portfolio AR is delayed
| Last 1 Week* | YTD*(2025) | 1 Yr | 3 Yr | 5 Yr | 10 Yr | 15 Yr | 15 Yr | 20 Yr | 20 Yr | Since 01/02/2001 |
2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Annualized Return(%) | 1.2 | 5.2 | 16.4 | 6.1 | 8.5 | 7.1 | 7.3 | 7.6 | 7.1 | 7.6 | 8.3 | 7.3 | 10.0 | -9.2 | 14.7 | 15.0 | 18.4 | -4.5 | 12.8 | 7.1 | -1.5 | 6.1 | 7.6 | 12.0 | 1.7 | 13.2 | 27.9 | -24.5 | 10.9 | 17.7 | 12.6 | 19.0 | 33.3 | 1.7 | 5.2 |
| Sharpe Ratio | NA | 0.22 | 0.15 | -0.01 | 0.5 | 0.52 | NA | NA | NA | NA | 0.68 | 0.09 | 0.84 | -0.98 | 1.57 | 0.81 | 2.98 | -0.7 | 2.96 | 0.82 | -0.2 | 1.06 | 1.16 | 1.82 | 0.14 | 1.21 | 1.48 | -1.08 | 0.75 | 1.97 | 1.7 | 2.36 | 6.23 | 0.1 | 0.41 |
| Draw Down(%) | NA | 1.6 | 6.6 | 14.3 | 19.8 | 22.1 | NA | NA | NA | NA | 38.8 | 5.8 | 6.1 | 15.9 | 4.2 | 22.1 | 2.8 | 10.5 | 2.1 | 5.4 | 8.7 | 4.5 | 7.2 | 5.2 | 10.5 | 8.2 | 17.3 | 38.2 | 6.5 | 8.6 | 4.4 | 10.2 | 2.2 | 11.0 | 9.4 |
| Standard Deviation(%) | NA | 6.3 | 7.5 | 8.6 | 11.3 | 9.5 | NA | NA | NA | NA | 10.3 | 7.8 | 6.9 | 10.8 | 9.3 | 18.2 | 5.7 | 8.2 | 4.1 | 8.4 | 7.9 | 5.8 | 6.5 | 6.5 | 11.7 | 10.9 | 18.7 | 23.6 | 10.5 | 7.3 | 6.2 | 7.7 | 5.2 | 5.8 | 7.1 |
| Treynor Ratio | NA | 0.03 | 0.02 | 0.0 | 0.12 | 0.1 | NA | NA | NA | NA | 0.15 | 0.01 | 0.13 | -0.26 | 0.25 | 0.3 | 0.45 | -0.13 | 0.28 | 0.13 | -0.03 | 0.13 | 0.14 | 0.25 | 0.03 | 0.23 | 0.43 | -0.47 | 0.13 | 0.24 | 0.23 | 0.37 | 1.73 | 0.04 | 0.13 |
| Alpha | NA | 0.02 | -0.01 | -0.01 | 0.0 | 0.0 | NA | NA | NA | NA | 0.02 | -0.03 | -0.01 | -0.01 | 0.0 | 0.02 | 0.02 | -0.01 | 0.02 | 0.01 | -0.01 | 0.0 | -0.03 | 0.02 | 0.0 | 0.02 | 0.04 | -0.02 | 0.03 | 0.03 | 0.04 | 0.05 | 0.09 | 0.02 | 0.02 |
| Beta | NA | 0.4 | 0.47 | 0.44 | 0.48 | 0.47 | NA | NA | NA | NA | 0.46 | 0.5 | 0.46 | 0.4 | 0.58 | 0.5 | 0.38 | 0.46 | 0.43 | 0.53 | 0.45 | 0.46 | 0.53 | 0.48 | 0.48 | 0.57 | 0.64 | 0.55 | 0.6 | 0.6 | 0.46 | 0.48 | 0.19 | 0.13 | 0.22 |
| RSquared | NA | 0.75 | 0.66 | 0.76 | 0.81 | 0.8 | NA | NA | NA | NA | 0.75 | 0.67 | 0.76 | 0.82 | 0.65 | 0.91 | 0.69 | 0.89 | 0.49 | 0.68 | 0.79 | 0.81 | 0.81 | 0.87 | 0.9 | 0.9 | 0.87 | 0.9 | 0.84 | 0.68 | 0.59 | 0.49 | 0.38 | 0.37 | 0.44 |
| Sortino Ratio | NA | 0.32 | 0.2 | -0.01 | 0.67 | 0.71 | NA | NA | NA | NA | 0.94 | 0.12 | 1.22 | -1.34 | 2.52 | 1.04 | 4.64 | -0.92 | 4.82 | 1.13 | -0.26 | 1.51 | 1.62 | 2.82 | 0.19 | 1.75 | 2.23 | -1.41 | 1.04 | 2.97 | 2.57 | 3.3 | 10.91 | 0.14 | 0.52 |
| Yield(%) | N/A | 0.2 | 2.1 | 3.2 | 4.6 | 4.7 | 6.0 | 6.0 | 7.6 | 7.6 | 3.93 | 2.2 | 3.7 | 3.5 | 6.6 | 2.9 | 3.5 | 2.6 | 3.7 | 3.7 | 2.9 | 3.4 | 2.6 | 3.6 | 3.4 | 3.2 | 3.5 | 4.3 | 6.2 | 5.1 | 4.4 | 4.7 | 3.7 | 3.5 | 5.1 |
| Dividend Growth(%) | N/A | -91.7 | -32.5 | -10.5 | 72.7 | 78.1 | N/A | N/A | N/A | N/A | N/A | -36.8 | -2.0 | -39.7 | 156.4 | -0.4 | 28.6 | -21.8 | 10.7 | 21.8 | -7.6 | 39.8 | -19.8 | 8.0 | 19.8 | 18.1 | -38.9 | -22.9 | 41.9 | 32.6 | 10.1 | 69.1 | 7.5 | -27.5 | N/A |
*: NOT annualized;YTD: Year to Date
**Inception: starting from 12/31/2000
Portfolio Description
This model portfolio uses Strategic Asset Allocation - Equal Weight
. The allocations are diversified by investing in the 5 major asset classes: US Equity, Emerging Market Equity, REITs, Fixed Income, Foreign Equity
that are covered in JOLIET ONCOLOGY HEMATOLOGY ASSOCIATES LTD. PROFIT SHARING/401K PLAN. It then selects one or two funds for each of the 5 major asset classes.
1.Risk allocation: the risk profile of this portfolio 40.
The total allocation of the fixed income assets should be at least 40%.
2.Asset weights: risk assets selected are equally weighted by
default.
3.Fund selection: about one or two top performing funds among 29 available funds in the plan are chosen for each asset selected. They are usually equally weighted within
the asset by default.
4.Rebalance frequency: the portfolio is reviewed by the strategy program monthly
and the above steps are repeated. Asset weights are rebalanced back to target allocation if it is necessary.
5.
Simulation: Performance data before this portfolio went public on
04/11/2020
are obtained from historical simulation. They are hypothetical.
Register for FREE
No Credit Card Required
Or Start FREE 30-day trial now >>
Or Start FREE 30-day trial now >>